{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:16Z","timestamp":1792153996544,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.vaccine.2011.06.034","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T01:48:00Z","timestamp":1309398480000},"page":"6008-6016","source":"Crossref","is-referenced-by-count":77,"title":["Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model"],"prefix":"10.1016","volume":"29","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Monath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.06.034_bib0005","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0010","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jama.300.8.960","article-title":"Yellow fever: 100 years of discovery","volume":"300","author":"Staples","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.trstmh.2007.06.013","article-title":"Acute viscerotropic disease following vaccination against yellow fever","volume":"101","author":"Hayes","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0020","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0025","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4269\/ajtmh.2010.10-0001","article-title":"Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978) United States","volume":"82","author":"Monath","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0035","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0040","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.292.14.1696","article-title":"Vaccine policy changes and epidemiology of poliomyelitis in the United States","volume":"292","author":"Alexander","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0045","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1016\/j.vaccine.2010.10.015","article-title":"Is it time for a new yellow fever vaccine?","volume":"28","author":"Hayes","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0050","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"A clinical trial of an inactivated, cell culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0060","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.vaccine.2004.03.027","article-title":"Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine","volume":"22","author":"Beasley","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0065","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1128\/JVI.77.24.12941-12949.2003","article-title":"Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice","volume":"77","author":"Engle","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0070","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1128\/JVI.01420-07","article-title":"Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody","volume":"81","author":"Lai","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.1993.1015","article-title":"The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice","volume":"192","author":"Schlesinger","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0080","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid0812.020229","article-title":"Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model","volume":"8","author":"Tesh","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0085","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus).I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0090","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1128\/AAC.01494-06","article-title":"Activity of T-1106 in a hamster model of yellow fever virus infection","volume":"51","author":"Julander","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.antiviral.2010.03.004","article-title":"Efficacy of 2\u2032-C-methylcytidine against yellow fever virus in cell culture and in a hamster model","volume":"86","author":"Julander","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound. T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4269\/ajtmh.2004.71.306","article-title":"Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease","volume":"71","author":"Sbrana","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2006.08.008","article-title":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model","volume":"73","author":"Julander","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0115","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0264-410X(98)00487-3","volume":"17","author":"Monath","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0120","series-title":"Vaccines","first-page":"17","article-title":"Vaccine immunology","author":"Siegrist","year":"2008"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0125","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, September 2\u20133, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0130","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1128\/JVI.00291-08","article-title":"Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo","volume":"82","author":"Goncalvez","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0135","first-page":"286","article-title":"Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies","volume":"141","author":"Kimura-Kuroda","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4269\/ajtmh.1973.22.535","article-title":"Passive immunity for arbovirus infection II. Quantitative aspects of naturally and artificially acquired protection in mice for Japanese (B) encephalitis","volume":"22","author":"Lubniecki","year":"1973","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/376870","article-title":"Prophylactic and therapeutic efficiency of human intravenous immunoglobulin in treating West Nile infection in mice","volume":"188","author":"Ben-Nathan","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0150","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1086\/508293","article-title":"Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters","volume":"194","author":"Morrey","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0155","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1128\/AAC.00147-07","article-title":"Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model","volume":"51","author":"Morrey","year":"2007","journal-title":"Antimicro Agents Chemother"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0160","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1128\/JVI.71.4.2921-2927.1997","article-title":"Pre-and post-exposure by passive immunoglobulin but not enhancement of infection with a flavivirus in a mouse model","volume":"71","author":"Kreil","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0165","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1128\/JVI.72.4.3076-3081.1998","article-title":"Neutralizing antibodies protect against lethal flavivirus challenge but allow for development of active humoral immunity y to a nonstructural protein","volume":"72","author":"Kreil","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0170","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0264-410X(97)00304-6","article-title":"Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model","volume":"16","author":"Kreil","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0175","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0264-410X(98)80102-3","article-title":"Vaccination against tick-borne encephalitis virus, a flavivirus, prevents disease but not infection, although viremia is undetectable","volume":"16","author":"Kreil","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","article-title":"Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D and dengue 2 viruses","volume":"76","author":"Brandiss","year":"1986","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1099\/0022-1317-67-3-591","article-title":"Neutralizing (54) and non-neutralizing (54k) and 48k) monoclonal antibodies and nonstructural yellow fever virus proteins confer immunity in mice","volume":"67","author":"Gould","year":"1986","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0190","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0195","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0205","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4269\/ajtmh.1999.61.288","article-title":"Japanese encephalitis vaccine (inactivated Biken) in U.S. soldiers: immunogenicity and safety of vaccine administration in two dosing regimes","volume":"61","author":"Defraites","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.034_bib0210","unstructured":"Prescribing information, IXIARO\u00ae (Japanese encephalitis vaccine, inactivated, absorbed), Intercell AG, 2009."},{"key":"10.1016\/j.vaccine.2011.06.034_bib0215","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1100898X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1100898X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T00:03:25Z","timestamp":1592697805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1100898X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":43,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0264410X1100898X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.06.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}